The Tau Consortium’s mission is to accelerate the development of new treatments for Alzheimer’s disease, frontotemporal dementias, and other neurodegenerative diseases involving the dysfunctional tau protein. We help scientists to work collaboratively, engage strategic partners who share our mission, and establish the critical resources needed to accelerate progress for understanding the underlying causes of these tau-related neurodegenerative diseases. Tau Consortium participants act with urgency and with patients in mind to develop novel approaches and cutting-edge treatments.

Since founding the Tau Consortium in 2009, the Rainwater Charitable Foundation has committed over $100 million to the program and has helped to put eight treatments into human trials.